These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 22066007)
1. Nevirapine plasma concentrations are associated with virologic response and hepatotoxicity in Chinese patients with HIV infection. Wang J; Kou H; Fu Q; Han Y; Qiu Z; Zuo L; Li Y; Zhu Z; Ye M; Ma Q; Li T PLoS One; 2011; 6(10):e26739. PubMed ID: 22066007 [TBL] [Abstract][Full Text] [Related]
2. Three generic nevirapine-based antiretroviral treatments in Chinese HIV/AIDS patients: multicentric observation cohort. Li T; Dai Y; Kuang J; Jiang J; Han Y; Qiu Z; Xie J; Zuo L; Li Y PLoS One; 2008; 3(12):e3918. PubMed ID: 19081791 [TBL] [Abstract][Full Text] [Related]
3. Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon. Mbougua JB; Laurent C; Kouanfack C; Bourgeois A; Ciaffi L; Calmy A; Gwet H; Koulla-Shiro S; Ducos J; Mpoudi-Ngolé E; Molinari N; Delaporte E BMC Public Health; 2010 Mar; 10():105. PubMed ID: 20193053 [TBL] [Abstract][Full Text] [Related]
4. The relationship between nevirapine plasma concentrations and abnormal liver function tests. Almond LM; Boffito M; Hoggard PG; Bonora S; Raiteri R; Reynolds HE; Garazzino S; Sinicco A; Khoo SH; Back DJ; Di Perri G AIDS Res Hum Retroviruses; 2004 Jul; 20(7):716-22. PubMed ID: 15307917 [TBL] [Abstract][Full Text] [Related]
5. Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients. Torti C; Costarelli S; De Silvestri A; Quiros-Roldan E; Lapadula G; Cologni G; Paraninfo G; Castelnuovo F; Puoti M; Carosi G; Drug Saf; 2007; 30(12):1161-9. PubMed ID: 18035868 [TBL] [Abstract][Full Text] [Related]
6. Low trough plasma concentrations of nevirapine associated with virologic rebounds in HIV-infected patients who switched from protease inhibitors. Duong M; Buisson M; Peytavin G; Kohli E; Piroth L; Martha B; Grappin M; Chavanet P; Portier H Ann Pharmacother; 2005 Apr; 39(4):603-9. PubMed ID: 15713788 [TBL] [Abstract][Full Text] [Related]
7. Comparison of nevirapine plasma concentrations between lead-in and steady-state periods in Chinese HIV-infected patients. Kou H; Du X; Li Y; Xie J; Qiu Z; Ye M; Fu Q; Han Y; Zhu Z; Li T PLoS One; 2013; 8(1):e52950. PubMed ID: 23359265 [TBL] [Abstract][Full Text] [Related]
12. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Cvetkovic RS; Goa KL Drugs; 2003; 63(8):769-802. PubMed ID: 12662125 [TBL] [Abstract][Full Text] [Related]
13. HBV, HCV, and HBV/HCV co-infection among HIV-positive patients in Hunan province, China: Regimen selection, hepatotoxicity, and antiretroviral therapy outcome. Su S; Fairley CK; Sasadeusz J; He J; Wei X; Zeng H; Jing J; Mao L; Chen X; Zhang L J Med Virol; 2018 Mar; 90(3):518-525. PubMed ID: 29091279 [TBL] [Abstract][Full Text] [Related]
14. Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study. Manfredi R; Calza L; Chiodo F J Acquir Immune Defic Syndr; 2004 Apr; 35(5):492-502. PubMed ID: 15021314 [TBL] [Abstract][Full Text] [Related]
15. Lack of effect from a previous single dose of nevirapine on virologic and immunologic responses after 6 months of antiretroviral regimens containing either efavirenz or lopinavir-ritonavir. Dlamini JN; Hu Z; Somaroo H; Highbarger HC; Follmann DA; Dewar RL; Pau AK Pharmacotherapy; 2011 Feb; 31(2):158-63. PubMed ID: 21275494 [TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics of toxicity, plasma trough concentration and treatment outcome with nevirapine-containing regimen in anti-retroviral-naïve HIV-infected adults: an exploratory study of the TRIANON ANRS 081 trial. Gozalo C; Gérard L; Loiseau P; Morand-Joubert L; Peytavin G; Molina JM; Dellamonica P; Becquemont L; Aboulker JP; Launay O; Verstuyft C; Basic Clin Pharmacol Toxicol; 2011 Dec; 109(6):513-20. PubMed ID: 21824325 [TBL] [Abstract][Full Text] [Related]
17. Prospective, open-label comparative study of liver toxicity in an unselected population of HIV-infected patients treated for the first time with efavirenz or nevirapine. Manfredi R; Calza L; Chiodo F HIV Clin Trials; 2005; 6(6):302-11. PubMed ID: 16452064 [TBL] [Abstract][Full Text] [Related]
18. Trough concentrations of lopinavir, nelfinavir, and nevirapine with standard dosing in human immunodeficiency virus-infected pregnant women receiving 3-drug combination regimens. Baroncelli S; Villani P; Floridia M; Pirillo MF; Galluzzo CM; Cusato M; Amici R; Pinnetti C; Sabbatini F; Molinari A; Tamburrini E; Regazzi M Ther Drug Monit; 2008 Oct; 30(5):604-10. PubMed ID: 18728627 [TBL] [Abstract][Full Text] [Related]
19. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. Ruiz L; Negredo E; Domingo P; Paredes R; Francia E; Balagué M; Gel S; Bonjoch A; Fumaz CR; Johnston S; Romeu J; Lange J; Clotet B; J Acquir Immune Defic Syndr; 2001 Jul; 27(3):229-36. PubMed ID: 11464141 [TBL] [Abstract][Full Text] [Related]